Rituximab and ABVD for Hodgkin's Patients
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT00504504
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
- Adriamycin — DRUG25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
- Bleomycin — DRUG10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
- Vinblastine — DRUG6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
- Dacarbazine (DTIC) — DRUG375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study Details
Primary Objective: \- To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.
Key Dates
- Start date
- Mar 31, 2001
- Status verified
- May 2013
- Primary completion
- Mar 31, 2012
- Completion
- Mar 31, 2012
Study Design
- Enrollment
- 85 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Rituximab + ABVD ChemotherapyRituximab 375 mg/m\^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m\^2 IV, Bleomycin 10 U/m\^2 IV, Vinblastine 6 mg/m\^2 IV, DTIC 375 mg/m\^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
Primary Outcome Measure
5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD [ Time Frame: Baseline to 5 Years or until disease progression ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD . Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Houston, TX
By research site
Related Studies
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALEPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant SurvivorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California